Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Operating Expenses (2016 - 2026)

Cumberland Pharmaceuticals' Other Operating Expenses history spans 16 years, with the latest figure at $9.5 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 23.57% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.8 million, a 5.09% increase, with the full-year FY2025 number at $29.8 million, changed N/A from a year prior.
  • Other Operating Expenses hit $9.5 million in Q4 2025 for Cumberland Pharmaceuticals, up from $6.4 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for CPIX hit a ceiling of $10.8 million in Q4 2023 and a floor of $6.1 million in Q3 2021.
  • Historically, Other Operating Expenses has averaged $7.5 million across 5 years, with a median of $7.3 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 66.9% in 2023 and later fell 29.27% in 2024.
  • Tracing CPIX's Other Operating Expenses over 5 years: stood at $7.6 million in 2021, then dropped by 15.17% to $6.5 million in 2022, then soared by 66.9% to $10.8 million in 2023, then fell by 29.27% to $7.7 million in 2024, then rose by 23.57% to $9.5 million in 2025.
  • Business Quant data shows Other Operating Expenses for CPIX at $9.5 million in Q4 2025, $6.4 million in Q3 2025, and $7.2 million in Q2 2025.